Credit Suisse Maintains Outperform on Olema Pharmaceuticals, Raises Price Target to $18
Portfolio Pulse from richadhand@benzinga.com
Credit Suisse analyst Richard Law maintains an 'Outperform' rating on Olema Pharmaceuticals (NASDAQ:OLMA) and raises the price target from $16 to $18.
August 09, 2023 | 1:29 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Credit Suisse maintains an 'Outperform' rating on Olema Pharmaceuticals and raises the price target from $16 to $18.
The news is directly related to Olema Pharmaceuticals. The 'Outperform' rating and raised price target by Credit Suisse indicate a positive outlook for the company, which could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100